Determining the Prevalence of HIV-Related Neurological Disorders in the Asia Pacific
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2007 by National Institute of Mental Health (NIMH).
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Collaborators:
The Alfred
Information provided by:
National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:
NCT00168246
First received: September 13, 2005
Last updated: February 26, 2007
Last verified: February 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will determine the prevalence of HIV-related neurological disorders in the countries of the Asia-Pacific Region.
| Condition |
|---|
|
HIV Infections HIV Related Neurological Diseases |
| Study Type: | Observational |
| Study Design: | Additional Descriptors: Convenience Sample Observational Model: Natural History Time Perspective: Cross-Sectional Time Perspective: Prospective |
| Official Title: | A Cross-Sectional Study of HIV-Related Neurological Disorders in Ten Countries of the Asia Pacific Region |
Resource links provided by NLM:
Further study details as provided by National Institute of Mental Health (NIMH):
| Estimated Enrollment: | 600 |
| Study Start Date: | June 2005 |
This a cross-sectional study to determine the prevalence of HIV-related Neurological Disorders in the countries of the Asia-Pacific Region. Researchers will visit each country site for a period of 2-3 weeks and work with local investigators. Outpatients will be evaluated once-only for the presence of HIV-related symptomatic peripheral neuropathy and HIV-related Neurocognitive Impairment. Inpatients at the sites will be evaluated once-only for the presence of HIV dementia, cerebral toxoplasmosis, cerebral tuberculosis, cryptococcal meningitis, lymphoma, PML and CMV encephalitis.
The Primary outcomes are:
- To determine the prevalence of HIV-related neurocognitive impairment and ADC at the APNAC-10 sites
- To determine the prevalence of symptomatic peripheral sensory neuropathy at the APNAC-10 sites
- To determine the prevalence of central nervous system opportunistic infections and tumours at the APNAC-10 sites
The secondary outcomes are:
To determine the degree of cognitive impairment in patients presenting with HIV-related cognitive impairment at the APNAC-10 sites
- To determine the CD4 cell counts, HIV viral loads HIV viral loads and prior AIDS defining illnesses (ADIs) of patients presenting with HIV-related neurocognitive impairment and ADC at the APNAC-10 sites
- To compare the prevalence of HIV-related neurocognitive impairment and ADC at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries
- To compare the prevalence of HIV-related neurocognitive impairment and ADC between the APNAC-10 sites
- To describe the severity of symptoms of patients presenting with symptomatic peripheral sensory neuropathy at the APNAC-10 sites
- To determine the CD4 cell counts, HIV viral loads HIV viral loads and prior ADIs of patients presenting with symptomatic peripheral sensory neuropathy at the APNAC-10 sites
- To determine what proportion of symptomatic peripheral sensory neuropathy may be ascribed to HIV alone, to the use of nucleoside analogues
- To compare the prevalence of symptomatic peripheral sensory neuropathy at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries
- To compare the prevalence of symptomatic peripheral sensory neuropathy between the APNAC-10 sites
- To determine the prevalence of asymptomatic peripheral neuropathy
- To describe the presenting symptoms and signs of patients presenting with CNS OIs and tumours at the APNAC-10 sites
- To describe the neuroradiological findings of patients presenting with CNS OIs and tumours at the APNAC-10 sites
- To determine the serological, culture and other diagnostic test results of patients presenting with CNS OIs and tumours at the APNAC-10 sites
- To determine the CD4 cell counts, HIV viral loads and prior ADIs of patients presenting with CNS OIs and tumours at the APNAC-10 sites
- To compare the prevalence of CNS OIs and tumours at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries
- To compare the prevalence of CNS OIs and tumours between the APNAC-10 sites
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
Criteria
Inclusion Criteria:
- Patients are HIV infected
- Patients are eighteen years or older
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00168246 History of Changes |
| Other Study ID Numbers: | 77/05 |
| Study First Received: | September 13, 2005 |
| Last Updated: | February 26, 2007 |
| Health Authority: | United States: Federal Government Australia: National Health and Medical Research Council |
Keywords provided by National Institute of Mental Health (NIMH):
|
HIV |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Nervous System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections |
Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on June 18, 2013